VivoSeq
Cardiovascular

Transient Ischemic Attack

16

Pipeline Programs↗

2

Active Trials↗

10

Companies Involved↗

Transient Ischemic Attack is an emerging landscape with 16 programs across 10 companies. The most active players are Orion Corporation, Orion Pharma, Boehringer Ingelheim, Sanofi. 2 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

78/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Orion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3Bayer logo

Bayer

3 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

16 of 17 classified programs — the dominant modality here.

6%ALL OTHERSPeptide16%

Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.

Analysis

Trial Status

14

clinical trials

Completed7 · 50%
Unknown status3 · 21%
Withdrawn2 · 14%
Recruiting1 · 7%
Not yet recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Statins in Frail Older Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study
Recruiting·—·N/A·NCT06785740·300 enrolled
StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial
Not yet recruiting·PProf. dr. Nathalie van der Velde·Phase 4·NCT06785727·612 enrolled
Preventing Recurrent Vascular Events in Patients With Stroke or Transient Ischemic Attack
Completed·UUniversity of Alberta·Phase 4·NCT00931788·279 enrolled
Biomarkers for the Diagnosis of Transient Ischemic Attack
Completed·UUniversity Hospital, Caen·N/A·NCT02799511·25 enrolled
Dabigatran Following Transient Ischemic Attack and Minor Stroke
Completed·UUniversity of Alberta·Phase 2·NCT02295826·300 enrolled
Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke
Completed·UUniversity of Alberta·Phase 2·NCT01769703·53 enrolled
Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3)
Completed·—·Phase 3·NCT05439356·8,343 enrolled
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
Completed·Bayer logoBayer·Phase 3·NCT05686070·12,327 enrolled
Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)
Completed·UUniversity of Calgary·Phase 2/3·NCT00109382·500 enrolled
Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack
Withdrawn·UUniversity of California, San Diego·Phase 1·NCT00363753
The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack
Withdrawn·UUniversity of Alberta·Phase 4·NCT02144831
Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease
Unknown status·Daewoong Pharmaceutical Co. LTD. logoDaewoong Pharmaceutical Co. LTD.·N/A·NCT02953405·1,000 enrolled
Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study
Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·N/A·NCT02975076·120 enrolled
Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus
Unknown status·FFirst Affiliated Hospital of Jinan University·N/A·NCT03948347·1,708 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)